ONEGUILD  ·  A MONTHLY LETTER · AUGUST 2026

A nationwide observational study in *Diabetes Care* (Bonnet et al., April 2026) drew on the French National Health Data System to follow 133,791 adults with an incident diabetic foot ulcer. Within a year, 14.6% had died and 3.5% had undergone major amputation — and of those amputated, 28.8% died within twelve months. Independent predictors of one-year mortality included older age, male sex, hospital-acquired DFU, insulin use, and the usual comorbidity burden. What is worth reading twice: GLP-1 receptor agonists, lipid-lowering therapy, and prior consultations with a diabetologist, ophthalmologist, or podiatrist were all independently associated with lower mortality — and the GLP-1 signal persisted after major amputation.

This is the third consecutive issue of Pulse in which the GLP-1 or SGLT2 story appears in a different guise — first as cardiorenal protection in T1D, then as safety in the setting of active wounds, now as post-ulcer survival. The pattern is not our editorial obsession; it is what this class is doing to the field. Bonnet's caveats are honest: observational, no HbA1c or smoking data, cannot distinguish T1D from T2D, medication dispensations rather than actual intake. But 133,791 patients is a large answer to a question the DFU community has rarely asked with mortality as the endpoint.

A commentary published in *Nature Reviews Nephrology* (Rossing and Heerspink, 13 August 2026) makes a point that we touched on last month in July when we covered the FINE-ONE trial and finerenone's FDA Priority Review for T1D-associated CKD. Their argument, in one sentence: despite unprecedented advances in treating CKD in the general population and in type 2 diabetes over the past decade, no new drugs have been approved for CKD in type 1 diabetes. The gap is not scientific — the mechanisms of glomerular injury share substantial ground across diabetes subtypes — it is a gap in trial design, in commercial priority, and in who counts as a study population worth enrolling.

Finerenone, if the FDA approves it later this year, will close part of this gap. But one drug is not a therapeutic architecture. Rossing and Heerspink call for coordinated action — from regulators, industry, and the T1D research community — to build a proper development pipeline for a population that landmark kidney trials have systematically excluded. For anyone working at the intersection of endocrinology and nephrology, this is worth reading in full.

A paper in *Nature* published this month (Guan, Kong, Ye et al., 12 August 2026) reports engineered probiotic bacteria equipped with a synthetic glucose-responsive genetic circuit. The bacteria transiently colonize the gut, sense rising glucose levels, and secrete therapeutic factors in response — a biological sense-and- respond loop delivered orally. In mouse models and in non-human primates, the system produced safe glycemic modulation without the pharmacokinetic constraints of conventional drugs. The design is transient by construction: the engineered strains do not permanently colonize, which addresses a common concern with genetically modified organisms in the gut.

This is early science. No human data yet, no clinical trial design published, and the regulatory pathway for glucose-responsive living therapeutics is genuinely uncharted. But conceptually, the paper matters beyond diabetes. It is one of the clearest demonstrations to date that we can build biological therapies that behave like circuits rather than like doses — programmable, responsive, and self-regulating. If any version of this reaches patients one day, the questions it raises about what "a diabetes treatment" even means are worth sitting with now.